As coronavirus concerns increase with the changing of the seasons, the most commonly used oral antiviral treatments are in the spotlight once again. Lagevrio acts by introducing mutations, destroying ...

A new study said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other people. But there is no evidence that molnupiravir, sold under the brand ...

The first pill shown to treat COVID-19 has moved one step closer to being available to the public. The pharmaceutical company Merck requested FDA emergency authorization Monday for their COVID-19 ...

Oct 26 (Reuters) - Merck & Co (MRK.N), opens new tab on Thursday reported higher-than-expected third-quarter results on surprisingly strong demand for its COVID-19 treatment, primarily in Japan, and ...

The U.S. government is set to cease the distribution of free doses of Merck & Co Inc's (NYSE:MRK) COVID-19 antiviral treatment Lagevrio (molnupiravir), by mid-November, shifting its availability to ...

WASHINGTON (AP) — Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world’s arsenal against the ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Merck (MRK) and Ridgeback Biotherapeutics announced today that their COVID-19 pill — the first oral antiviral of its kind — cut the risk of hospitalizations or deaths by half, and that they would ...

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.